202 related articles for article (PubMed ID: 20111067)
1. MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms.
Patnaik MM; Lasho TL; Finke CM; Gangat N; Caramazza D; Siragusa S; Hanson CA; Pardanani A; Tefferi A
Leukemia; 2010 Apr; 24(4):859-60. PubMed ID: 20111067
[No Abstract] [Full Text] [Related]
2. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
[TBL] [Abstract][Full Text] [Related]
3. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
4. JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia.
Andrikovics H; Nahajevszky S; Koszarska M; Meggyesi N; Bors A; Halm G; Lueff S; Lovas N; Matrai Z; Csomor J; Rasonyi R; Egyed M; Varkonyi J; Mikala G; Sipos A; Kozma A; Adam E; Fekete S; Masszi T; Tordai A
Leukemia; 2010 Oct; 24(10):1809-13. PubMed ID: 20811399
[No Abstract] [Full Text] [Related]
5. Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms.
Chen X; Qi X; Tan Y; Xu Z; Xu A; Zhang L; Wang H
Blood Cells Mol Dis; 2011 Jun; 47(1):67-71. PubMed ID: 21555228
[TBL] [Abstract][Full Text] [Related]
6. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
[TBL] [Abstract][Full Text] [Related]
7. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms.
Shirane S; Araki M; Morishita S; Edahiro Y; Takei H; Yoo Y; Choi M; Sunami Y; Hironaka Y; Noguchi M; Koike M; Noda N; Ohsaka A; Komatsu N
Haematologica; 2015 Feb; 100(2):e46-8. PubMed ID: 25398833
[No Abstract] [Full Text] [Related]
8. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
Zhang SJ; Qiu HX; Li JY; Shi JY; Xu W
Int J Lab Hematol; 2010 Aug; 32(4):381-6. PubMed ID: 20331763
[TBL] [Abstract][Full Text] [Related]
9. Different lineage involvement in myelodysplastic/myeloproliferative disease with combined MPLW515L and JAK2V617F mutation.
Hussein K; Theophile K; Buhr T; Beller A; Kreipe H; Bock O
Br J Haematol; 2009 Jun; 145(5):673-5. PubMed ID: 19344408
[No Abstract] [Full Text] [Related]
10. Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders.
Ghaderi M; Strömberg O; Porwit A
Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):122-6. PubMed ID: 19016916
[TBL] [Abstract][Full Text] [Related]
11. Pathology consultation on myeloproliferative neoplasms.
Schmidt AE; Oh ST;
Am J Clin Pathol; 2012 Jul; 138(1):12-9. PubMed ID: 22706852
[TBL] [Abstract][Full Text] [Related]
12. The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms.
Soler G; Bernal-Vicente A; Antón AI; Torregrosa JM; Caparrós-Pérez E; Sánchez-Serrano I; Martínez-Pérez A; Sánchez-Vega B; Vicente V; Ferrer-Marin F
Ann Hematol; 2015 May; 94(5):789-94. PubMed ID: 25482455
[TBL] [Abstract][Full Text] [Related]
13. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.
Olcaydu D; Rumi E; Harutyunyan A; Passamonti F; Pietra D; Pascutto C; Berg T; Jäger R; Hammond E; Cazzola M; Kralovics R
Haematologica; 2011 Mar; 96(3):367-74. PubMed ID: 21173100
[TBL] [Abstract][Full Text] [Related]
14. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
[TBL] [Abstract][Full Text] [Related]
15. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations.
Vannucchi AM; Guglielmelli P
Haematologica; 2008 Jul; 93(7):972-6. PubMed ID: 18591622
[No Abstract] [Full Text] [Related]
17. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.
Jones AV; Campbell PJ; Beer PA; Schnittger S; Vannucchi AM; Zoi K; Percy MJ; McMullin MF; Scott LM; Tapper W; Silver RT; Oscier D; Harrison CN; Grallert H; Kisialiou A; Strike P; Chase AJ; Green AR; Cross NC
Blood; 2010 Jun; 115(22):4517-23. PubMed ID: 20304805
[TBL] [Abstract][Full Text] [Related]
18. JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms.
Wang J; Xu Z; Liu L; Gale RP; Cross NC; Jones AV; Qin T; Ai X; Xu J; Zhang T; Sun X; Li Q; Zhang P; Zhang Y; Xiao Z
Leukemia; 2013 Aug; 27(8):1763-7. PubMed ID: 23337930
[No Abstract] [Full Text] [Related]
19. Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation.
Hussein K; Bock O; Theophile K; Schlue J; Ballmaier M; Kröger N; Göhring G; Büsche G; Kreipe H
Blood; 2009 Feb; 113(6):1391-2. PubMed ID: 19196872
[No Abstract] [Full Text] [Related]
20. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
Gong JZ; Cook JR; Greiner TC; Hedvat C; Hill CE; Lim MS; Longtine JA; Sabath D; Wang YL;
J Mol Diagn; 2013 Nov; 15(6):733-44. PubMed ID: 23978506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
